As AACR 2024 came to a close, one of the most exciting themes to emerge was the rapid progress in antibody-drug conjugates (ADCs), with particular attention on bispecific ADCs (BsADCs). These new therapies are drawing significant interest for their potential to expand treatment options across a wide range of solid tumors.
Below are some of the most noteworthy therapies highlighted at the conference:
- Innovent IBI3001: A potentially first-in-class bispecific ADC against B7-H3 and Her2. This well-tolerated and site-specific glycan conjugate can be used to treat multiple solid tumors, demonstrating robust anti-tumor efficacy in vitro and in vivo across a range of solid tumors.
- Innovent IBI334: A novel ADCC-enhanced B7-H3/Her2 bispecific antibody that has demonstrated improved tumor growth inhibition in vitro and in vivo compared to c-met/Her2 bispecific antibody and Her2 monoclonal antibody benchmarks.
- Alphamab JSKN003-101: An anti-HER2 bispecific ADC suitable for the treatment of HER2-expressing advanced solid tumors. JSKN003 has been shown to exhibit favorable tolerability and a good safety profile. It has also been shown to encourage preliminary antitumor activity in patients with HER2-expressing advanced or metastatic solid tumors.
These highlights are just the start. The AACR 2024 Research Highlights eBook takes a closer look at the latest breakthroughs in bispecific ADCs and other emerging cancer therapies, with insights you can put into context.
About ACROBiosystems
ACROBiosystems is a cornerstone enterprise of the pharmaceutical and biotechnology industries. Their mission is to help overcome challenges with innovative tools and solutions from discovery to the clinic. They supply life science tools designed to be used in discovery research and scalable to the clinical phase and beyond. By consistently adapting to new regulatory challenges and guidelines, ACROBiosystems delivers solutions, whether it comes through recombinant proteins, antibodies, assay kits, GMP-grade reagents, or custom services. ACROBiosystems empower scientists and engineers dedicated towards innovation to simplify and accelerate the development of new, better, and more affordable medicine.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.